How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,755 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Early morphea simulating patch-stage mycosis fungoides in two cases (PubMed)

Early morphea simulating patch-stage mycosis fungoides in two cases Morphea is a skin disorder characterized by thickening of dermis and subcutaneous tissues and loss of adnexal structures. In the early inflammatory stage of morphea, diagnostic histological findings are absent and this may lead to confusion with other inflammatory dermatoses such as mycosis fungoides (MF). We report two cases of early stage morphea mimicking patchstage of MF. Histopathologic examination of biopsies obtained

Full Text available with Trip Pro

2018 Dermatology Reports

62. Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides (PubMed)

Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides Total skin electron beam therapy (TSEBT) is an effective treatment in mycosis fungoides. Total skin helical tomotherapy (TSHT) may be an alternative to TSEBT and may offer several dosimetric and treatment advantages. There are currently very few published treatment results using TSHT in place of TSEBT for treatment of mycosis fungoides.Two patients with mycosis fungoides were (...) had been treated for mycosis fungoides using helical tomotherapy (HT) at a dose of 20 Gy to a localized region and experienced mild thrombocytopenia at that time. The patient then underwent retreatment 17 months later with TSHT to a dose of 12 Gy in 6 fractions with a mean bone marrow dose of 2.3 Gy and V10 = 4.28%. This patient once again experienced myelosuppression that included grade 4 thrombocytopenia. She also required blood and platelet transfusions.Both patients treated with TSHT

Full Text available with Trip Pro

2018 Radiation oncology (London, England)

63. Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia (PubMed)

Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia Patients with mycosis fungoides (MF), the most common subtype of primary cutaneous T-cell lymphoma, have an increased risk of developing secondary malignancies. We herein report two rare cases of MF concurring with diffuse large B cell lymphoma (B lymphoid lineage) and acute myeloid leukemia (myeloid lineage) in two otherwise healthy elderly patients. Potential etiologic factors, including

Full Text available with Trip Pro

2018 Internal Medicine

64. Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy (PubMed)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use (...) for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

Full Text available with Trip Pro

2018 Case reports in oncology

65. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data (PubMed)

Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data Nitrogen mustard is a chemotherapeutic agent that has a well-documented safety and efficacy profile in the treatment of cutaneous T-cell lymphoma. Development of nitrogen mustard formulations and treatment regimens has been studied extensively over the last 40 years. In the last 5 years, a new gel formulation has been developed

Full Text available with Trip Pro

2018 Drug design, development and therapy

66. A unique combination of Rosai-Dorfman disease and mycosis fungoides: a case report (PubMed)

A unique combination of Rosai-Dorfman disease and mycosis fungoides: a case report Rosai-Dorfman disease (RDD) is a rare histiocytic condition of unknown etiology. Patients with RDD classically present with massive painless cervical lymphadenopathy. However, extra-nodal disease occurs in approximately 40% of cases, with the skin being among the most commonly involved sites. Patients with isolated extra-nodal involvement may present without adenopathy. Reports of RDD occurring in patients (...) with Hodgkin's lymphoma, and B-cell lymphoma have been published, but there has only been one previous report of RDD in a patient with a T-cell lymphoma. This case report documents a unique combination of RDD and mycosis fungoides (MF), a cutaneous T cell lymphoma. This report also highlights diagnostic challenges in RDD due to the rarity of the condition and its variable presentation.

Full Text available with Trip Pro

2018 SAGE Open Medical Case Reports

67. A case of acute heart failure due to myocardial infiltration of mycosis fungoides (PubMed)

A case of acute heart failure due to myocardial infiltration of mycosis fungoides Mycosis fungoides (MF) has been reported to be the most common cutaneous lymphoma with a good prognosis and myocardial infiltration is clinically rare. We hereby report a case of rapidly progressing acute heart failure due to myocardial infiltration by MF. Perfusion cardiac magnetic resonance imaging (MRI) demonstrated a massive perfusion defect in the left ventricle (LV) where multiple nodular enhancement areas (...) by delayed enhancement MRI could be documented in the postero-lateral wall of the LV, which resulted in a deterioration of the LV function and mitral regurgitation. Autopsy confirmed the myocardial infiltration by the MF, which corresponded with the MRI findings. mycosis fungoides (MF) have a poor prognosis because they could not undergo chemotherapy for primary disease. Therefore, early diagnosis is important

Full Text available with Trip Pro

2018 Journal of cardiology cases

68. Total Skin Electron Beam Therapy with Rotary Dual Technique as Palliative Treatment for Mycosis Fungoides (PubMed)

Total Skin Electron Beam Therapy with Rotary Dual Technique as Palliative Treatment for Mycosis Fungoides The aim of the study was to retrospectively assess the efficacy and toxicity of total skin electron beam therapy (TSEBT) in patients with primary cutaneous T-cell lymphoma (MF, mycosis fungoides) at various stages of development.Treatment results of 40 patients with MF stage IB-III, treated between 2001 and 2015, were reviewed. Median total dose was 32 Gy, delivered to the entire skin

Full Text available with Trip Pro

2018 In Vivo

69. The importance of lymph node examination: Simultaneous diagnosis of hypopigmented mycosis fungoides and follicular B-cell lymphoma (PubMed)

The importance of lymph node examination: Simultaneous diagnosis of hypopigmented mycosis fungoides and follicular B-cell lymphoma 29942830 2019 02 26 2352-5126 4 6 2018 Jul JAAD case reports JAAD Case Rep The importance of lymph node examination: Simultaneous diagnosis of hypopigmented mycosis fungoides and follicular B-cell lymphoma. 590-592 10.1016/j.jdcr.2018.05.017 Joseph Mathew X MX Division of Dermatology, Medical College of Georgia at Augusta University, Augusta, Georgia. Brown Ashley D (...) AD Division of Dermatology, Medical College of Georgia at Augusta University, Augusta, Georgia. Davis Loretta S LS Division of Dermatology, Medical College of Georgia at Augusta University, Augusta, Georgia. eng Case Reports 2018 06 19 United States JAAD Case Rep 101665210 2352-5126 CTCL, cutaneous T-cell lymphoma MF, mycosis fungoides NHL, non-Hodgkin lymphoma bcl, B-cell lymphoma gene cutaneous T-cell lymphoma follicular B-cell lymphoma mycosis fungoides simultaneous diagnosis 2018 6 27 6 0

Full Text available with Trip Pro

2018 JAAD Case Reports

70. Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03617224 Recruitment Status : Recruiting

2018 Clinical Trials

71. Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides

Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ultra (...) Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03398161 Recruitment Status : Recruiting First Posted : January 12, 2018 Last Update Posted : August

2018 Clinical Trials

72. Dosing of Brentuximab Vedotin for Mycosis Fungoides Patients

Dosing of Brentuximab Vedotin for Mycosis Fungoides Patients Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dosing (...) of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03587844 Recruitment Status : Recruiting First Posted : July 16, 2018 Last Update Posted : February 15, 2019

2018 Clinical Trials

73. SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

74. Folliculotropic CD8+ mycosis fungoides associated with diffuse mucosal involvement (PubMed)

Folliculotropic CD8+ mycosis fungoides associated with diffuse mucosal involvement 30246124 2019 02 26 2352-5126 4 8 2018 Sep JAAD case reports JAAD Case Rep Folliculotropic CD8 + mycosis fungoides associated with diffuse mucosal involvement. 777-779 10.1016/j.jdcr.2018.04.005 de Masson Adèle A Dermatologie, Höpital Saint-Louis, APHP, Paris, France. Université Paris Diderot, Paris, France. Frumholtz Laure L Dermatologie, Höpital Saint-Louis, APHP, Paris, France. Battistella Maxime M Université (...) , Paris, France. Université Paris Diderot, Paris, France. Cordoliani Florence F Dermatologie, Höpital Saint-Louis, APHP, Paris, France. eng Case Reports 2018 09 14 United States JAAD Case Rep 101665210 2352-5126 CD8 FMF, folliculotropic mycosis fungoides MF, mycosis fungoides TRM, resident memory T cells folliculotropism mucosa mycosis fungoides 2018 9 25 6 0 2018 9 25 6 0 2018 9 25 6 1 epublish 30246124 10.1016/j.jdcr.2018.04.005 S2352-5126(18)30105-X PMC6141727 J Exp Med. 2010 Mar 15;207(3):553-64

Full Text available with Trip Pro

2018 JAAD Case Reports

75. Commentary to “Mogamulizumab‐induced photosensitivity in patients with mycosis fungoides and other T‐cell neoplasms” by Y. Masuda et al. (PubMed)

Commentary to “Mogamulizumab‐induced photosensitivity in patients with mycosis fungoides and other T‐cell neoplasms” by Y. Masuda et al. 30303306 2018 12 07 1468-3083 32 10 2018 Oct Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Commentary to "Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms" by Y. Masuda et al. 1626 10.1111/jdv.15214 Hönigsmann H H Department of Dermatology

Full Text available with Trip Pro

2018 Journal of the European Academy of Dermatology and Venereology

76. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. (PubMed)

Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. Advanced age at diagnosis is considered a poor prognostic factor in mycosis fungoides (MF) and Sézary syndrome (SS).To evaluate the outcomes and prognostic factors in patients diagnosed at an advanced age (≥65 years) with MF/SS.Survival, progression rates and various clinical and histopathological variables were studied in a group of 174

Full Text available with Trip Pro

2018 Journal of the European Academy of Dermatology and Venereology

77. Local radiation and phototherapy most cost-effective treatments for stage IA mycosis fungoides: a comparative decision-analysis model in the United States. (PubMed)

Local radiation and phototherapy most cost-effective treatments for stage IA mycosis fungoides: a comparative decision-analysis model in the United States. Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy

2018 Journal of American Academy of Dermatology

78. Infectious events and associated risk factors in Mycosis Fungoides/Sézary Syndrome: a retrospective cohort study. (PubMed)

Infectious events and associated risk factors in Mycosis Fungoides/Sézary Syndrome: a retrospective cohort study. Infections are one of the major causes of death in patients with advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS). However, few recent data are available on the characteristics and risk factors of these infectious events.To describe infectious events occurring in a cohort of patients with MF/SS, and to identify associated clinical and biological risk factors.A

2018 British Journal of Dermatology

79. Specific TCR gene rearrangements in mycosis fungoides: does advanced clinical stage show a preference? (PubMed)

Specific TCR gene rearrangements in mycosis fungoides: does advanced clinical stage show a preference? The relationship between the presence of specific T-cell receptor (TCR) gene rearrangements and clinical stage in mycosis fungoides (MF) has not been studied. We analysed a cohort of patients with a diagnosis of MF to determine the different types of specific TCR gene rearrangements present and their relationship to disease stage.A retrospective chart review was used to select patients

2018 Journal of Clinical Pathology

80. Folliculotropic Mycosis fungoides associated with GATA2 deficiency: a new skin manifestation. (PubMed)

Folliculotropic Mycosis fungoides associated with GATA2 deficiency: a new skin manifestation. 30101490 2018 12 03 1365-2133 179 6 2018 Dec The British journal of dermatology Br. J. Dermatol. Folliculotropic mycosis fungoides associated with GATA2 deficiency: a new skin manifestation. 1420-1421 10.1111/bjd.17081 Fertitta L L http://orcid.org/0000-0003-3528-9804 Department of Dermatology. Fontbrune F Sicre de FS Department of Haematology. Battistella M M Department of Pathology and. De Masson

2018 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>